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Esophageal atresia with or without tracheoesophageal fistula (EA±TEF) occurs in 1 out of
every 3000 births. Current survival approaches 95%, and research is therefore focused on
morbidity and health-related quality of life issues. Up to 50% of neonates with EA±TEF
have one or more additional malformations including those of the respiratory tract that
occur in a relatively high proportion of them and particularly of those with vertebral, anal, car-
diac, tracheoesophageal, renal, and limb association. Additionally, a significant proportion
of survivors suffer abnormal pulmonary function and chronic respiratory tract disease. The
present review summarizes the current knowledge about the nature of these symptoms
in patients treated for EA±TEF, and explores the hypothesis that disturbed development
and maturation of the respiratory tract could contribute to their pathogenesis.
Keywords: esophageal atresia, tracheoesophageal fistula, respiratory tract disease, lung, development, human,
rodent models
INTRODUCTION
Progress in surgical techniques and perinatal care allowed dra-
matic improvement of survival in the decades elapsed since the
first successful primary repair of esophageal atresia with tracheoe-
sophageal fistula (EA±TEF) in 1941 (1). However, even after an
uneventful postoperative course, a large proportion of these chil-
dren suffer long-standing respiratory tract disease. This is, in fact,
as frequent in EA±TEF survivors as in children operated upon
for congenital diaphragmatic hernia, a condition in which lung
hypoplasia and pulmonary hypertension are frequent (2). The per-
sistent respiratory symptoms found in children with EA±TEF are
recurrent bronchitis, brassy cough, chronic cough, repeated pneu-
monia, and asthma-like wheezing. Although some of them may
be accounted for by documented tracheomalacia, esophageal dys-
motility, gastroesophageal reflux (GER), or surgical complications,
up to 75% of survivors still have abnormal pulmonary function
(obstructive/restrictive) apparently not related to these abovemen-
tioned conditions (3, 4). Although respiratory morbidity tends to
improve with age, the chronic cough, bronchial constriction and
hyper-responsiveness can persist or even become more frequent
in adulthood (5–7).
The common origin of both the digestive and respiratory sys-
tems from the embryonic foregut explains why abnormal regu-
lation of its development causes malformations of both systems.
Accumulating evidence suggests that lung lesions acquired dur-
ing early development can lead to persistent structural damage
and respiratory function impairment during postnatal life. The
present review examines the link between disturbed lung devel-
opment during embryogenesis of EA±TEF and the respiratory
morbidity in patients with this malformation.
RESPIRATORY TRACT DISEASE IN EA± TEF SURVIVORS
Patients with EA±TEF suffer respiratory symptoms more often
and more persistently than other individuals. In the long term, they
are reported in up to 72% of surviving adolescents and adults (4,
8, 9). The most frequent symptoms are chronic (ranging from 8 to
86%) and barky cough (24–75%), bronchitis (14–74%), dyspnea
on exertion or poor tolerance to exercise (19–37%), and pneumo-
nia (34–48%) (3, 4, 8–14). Doctor-diagnosed asthma, atopy, and
bronchial hyper-responsiveness also appear to be quite frequent
with prevalences ranging from 16 to 65% (4, 8–15). In fact, atopy
is responsible for a significant proportion of respiratory morbidity
in older patients whose inflammatory profile based on bronchial
biopsies and exhaled nitric oxide differs from the typical asthma
patients (16).
Abnormal pulmonary function tests are demonstrated in up
to 96% of children, adolescents, and adults previously treated
for EA±TEF (14). The restrictive (35–57%) pattern prevails
over the obstructive (11–55%) or mixed ones (3, 4, 8). Legrand
et al. reported abnormal spirometry not related to prematurity;
intrauterine growth retardation; associated anomalies; vertebral,
anal, cardiac, tracheoesophageal, renal, limb (VACTERL) asso-
ciation; esophageal dilations; gastrostomy; fundoplication; and
GER or dysphagia in 75% of EA±TEF survivors (3). Peetsold
et al. also found that restrictive impairments were similarly fre-
quent in EA±TEF patients irrespective of the need for anti-reflux
surgery (13).
Although accumulating data suggest that respiratory symptoms
in these patients improve with age, their quality of life is signifi-
cantly impaired for these reasons when they become adults (4). In
fact, chronic cough and wheezing do not improve with age and in a
subset of patients even become more frequent (4–7). Lilja et al. in a
large study with 125 EA±TEF survivors ranging from 1 to 20 years
of age reported that shortness of breath (53%) and respiratory
infections (40%) were more frequent in the group aged 16–20 than
in the groups aged 1–5 (36 and 11%, respectively), 6–10 (21 and
25%, respectively), and 11–15 (38 and 56%, respectively); other
frequent symptoms such as coughing, impaired exercise capacity,
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and asthma medication had a similar or slightly reduced preva-
lence in the oldest group (1–5 years group: 43, 27, and 35% vs.
16–20 years groups: 36, 20, and 36%, respectively) (7).
Finally, respiratory complications are major causes of early
death in EA±TEF patients immediately following cardiac mal-
formations and chromosomal anomalies, and are even the main
reasonable responsible for late deaths (the majority occurring
during the first year of life) (17–19).
EPIDEMIOLOGY OF EA± TEF AND ASSOCIATED
RESPIRATORY MALFORMATIONS
EA±TEF occurs in 1 per 3000 live births. It is two to three times
more common in twins, and although most cases are sporadic, as
many as 10% are associated with chromosomal anomalies (20).
Trisomies and several syndromes and associations have EA±TEF
as a feature such as anophthalmia–esophageal–genital (AEG);
coloboma; heart anomaly; choanal atresia, retardation, genital, and
ear (CHARGE); Feingold or X-linked Opitz syndromes; and the
most commonly related VACTERL association. The spectrum of
the malformation comprises five anatomical subtypes: EA with
distal TEF (86%) followed by isolated EA without TEF (7%),
TEF without EA (4%), EA with proximal TEF (2%), and EA with
proximal and distal TEF (<1%) (20).
Approximately 50% of neonates with EA±TEF have one
or more additional malformations: cardiovascular (29%), anal
(14%), genitourinary (14%), gastrointestinal (13%), or skeletal
(10%) (20). Respiratory malformations are present in 6% of chil-
dren with EA±TEF (and in 13% of those who came to necropsy).
These proportions go up to 47% in patients with the VACTERL
association (20–22). Hypoplasia, fusion (horseshoe) or agenesis
of the lung (23–29), and structural, innervatory, and epithelial
differentiation anomalies of the tracheobronchial tree have been
described in this condition (22, 30–33).
MECHANISMS OF EA± TEF
The etiology of EA±TEF is largely unknown. Isolated EA±TEF
is probably caused by an insult that occurs during the narrow
gestational window of tracheoesophageal cleavage. Very little is
known about its causes. The lack of a heritable pattern and the
evidence that environmental agents acting in utero in human
individuals such as maternal alcohol use, phenylketonuria, dia-
betes, and metamizole or intrauterine exposure to adriamycin and
levothyroxine in rodents support a multifactorial origin (34–36).
However, in cases of syndromic EA±TEF, trisomies and other
chromosomal anomalies as well as several genetic pathways involv-
ing genes such as N-MYC, SOX2, and CDH7 have been shown to
contribute to the pathogenesis (37).
The precise mechanisms of tracheoesophageal malformations
are still unclear. Nevertheless, the recent development of ani-
mal models that closely mimics the human phenotype allowed
significant advances in understanding of the dysmorphogenetic
processes.
During the fourth week of embryonic life in humans and
around day 12 in rats, the foregut endoderm differentiates into
a ventral respiratory part and a dorsal esophageal part. After
emergence of the tracheobronchial bud from the floor of the
foregut, the respiratory and esophageal parts of the foregut begin to
separate. The mechanism that underlies the failure of this process
of separation leading to EA±TEF is still a matter of debate. Fail-
ure of tracheal growth or esophageal atresia has been proposed
as primary pathogenic occurrences (38). Regarding the cleavage
process itself, various interpretations have been discussed: rapid
cranial esophageal growth; rapid caudal esophageal, tracheal, and
interposed mesenchymal growth; and rapid growth of the mes-
enchymal septum interposed between both actively elongating
foregut-derived structures and the “folds fusion” theory (39, 40).
Evidence from genetic and toxicologic models (Noggin knock-
out mice and adriamycin-exposed rats, both with up to 70% of tra-
cheoesophageal malformations) implies an abnormal notochord
shaping in the failed tracheoesophageal separation (36, 41, 42).
In the toxicologic animal model, this early deformed embryonic
structure is associated with a disturbed temporospatial pattern
of expression of the key developmental gene Sonic hedgehog (Shh)
and members of its signaling cascade suggesting that in the normal
development, a precise Shh gradient is necessary for separation of
the trachea and the esophagus (40, 43).
THE HUMAN CONDITION
In isolated EA±TEF, despite a twinning rate (3.5–5%) signifi-
cantly higher than in general population (1–2%) and the 1% risk
in offspring, the available data do not support a genetic heritabil-
ity (34). A multifactorial origin with environmental and genetic
players is generally accepted. In syndromic EA±TEF, trisomies
13, 18 or 21 and other chromosomal rearrangements account
for 6–10% of cases (44, 45). Although no single specific chro-
mosomal defect has been recognized as an established etiolog-
ical factor, mutations in MYCN, CHD7, SOX2, MID1, and Gli3
genes were identified in malformative genetic disorders featur-
ing EA±TEF such as Feingold, CHARGE, AEG, X-linked Opitz,
and Pallister–Hall syndromes, respectively (37). These syndromes
are not characterized by a disturbed lung phenotype but, interest-
ingly, all these genes involved are expressed during embryonic lung
development. MYCN (or N-myc proto-oncogene that encodes
a protein with a basic helix–loop–helix domain) is ubiquitously
expressed in early development and at Carnegie stage 15 is dif-
ferentially and highly expressed in the esophageal and bronchial
epithelia. Furthermore, targeted inactivation of the orthologous
murine N-myc gene revealed its function in the development of
the gut and in the branching morphogenesis of the lung, in a way
that mutant mice with 25% of wild-type levels of N-myc pro-
tein are unable to breathe because of severe deficiency in lung
branching (46, 47).CHD7 (chromodomain helicase DNA-binding
protein 7) is expressed in organs affected by CHARGE syndrome
but is widely expressed during fetal development with high lev-
els in epithelial cells of the lung and gut (48). SOX2 (member of
the SRY-related HMG-box family of transcription factors) is cru-
cial for foregut organogenesis and is transcriptionally expressed
during esophageal, tracheal, and lung development. In addition,
hypomorphic SOX2 mutant mice exhibit EA–TEF phenotype and
abnormal differentiation of the epithelium lining the conducting
airways in the lung (41, 49). MID1 (a member of the RING-B box-
coiled coil subgroup of RING finger proteins) is expressed in lung
and esophageal epithelium of human embryos, and experimen-
tal data suggest a negative influence in Shh expression (50, 51).
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Finally, Gli3 is a transcription factor that mediates the Shh sig-
naling, a critical pathway in foregut and lung morphogenesis
(mutant mice forGli3 exhibit tracheoesophageal and lung defects)
(40, 52, 53).
ANIMAL MODELS
Studies on knockout mice demonstrate the involvement of devel-
opmental genes such as Shh, Gli2, Gli3, SOX2, TTF1, Foxf1,
RAR α, and RAR β in abnormal tracheoesophageal phenotypes
(37, 40).
The spectrum of malformations exhibits varying degrees of
severity depending on gene dosage. The esophageal/tracheal phe-
notype is always accompanied by disturbances of lung develop-
ment and/or differentiation ranging from agenesis or hypoplasia
to lung immaturity or lobulation defects (45). The fact that the
abnormal notochord of fetal rats treated in utero with adriamycin
and bearing EA±TEF exhibits a disturbed Shh gradient also sup-
ports the involvement of this gene. Shh signaling is a crucial
pathway that modulates both digestive and respiratory embryo-
genesis. In fact, lung hypoplasia with abnormal Shh lung signaling
and FGF10 expression in adriamycin-exposed rats with EA–TEF
was recently reported [52, 54, Fragoso et al. (submitted to publica-
tion)]. In summary, the abovementioned genes plus BMP family
members implicated in the animal EA–TEF phenotype are key
developmental morphogens for both the digestive and respiratory
systems modulating esophagus and lung embryogenesis.
MULTIFACTORIAL ORIGIN OF RESPIRATORY TRACT DISEASE
IN EA± TEF SURVIVORS
Respiratory tract malformations or dysfunctions account for a
part of the symptoms suffered by EA±TEF survivors but abnor-
mal function of the gastrointestinal tract, so closely related to the
airway, plays a role as well.
IMMATURITY AND LOW BIRTH WEIGHT
Small for gestational age neonates represent a high-risk group
regarding neonatal pulmonary morbidity (55). According to the
literature, 20–40% of esophageal atresia babies are born prema-
turely (<37 weeks) and have low birth weight (56, 57). Deurloo
et al. reported that birth weight <2500 g was associated with a
complicated clinical evolution during the first year of life although
the incidence of preoperative respiratory problems was similar to
that of babies born at term (56). Furthermore, Calisti et al. did
not find a clear correlation between adverse perinatal conditions
(need for ventilatory support at birth, immaturity, or low birth
weight) and higher incidence of long-term sequelae, like recurrent
respiratory infection and GER in EA±TEF patients (58). Finally,
Legrand et al. reported that neither prematurity nor intrauterine
growth retardation was associated with late respiratory symptoms
or abnormal spirometry results (3).
ESOPHAGEAL DYSMOTILITY AND GER
The motility of the esophagus is always disturbed in patients
with EA±TEF. Several factors may contribute to this condition
like a primary abnormal innervation disorder (59–62) and/or
secondary vagal nerve damage during surgical repair (63, 64).
Disturbed intrinsic innervation, deficient extrinsic nerve plexus,
abnormal neural markers, and altered enteric nerve morphology
are also characteristics of the atretic esophagus in the rat and
mouse models of EA±TEF (65–68). These intrinsic anatomic
anomalies and/or surgical issues are the main causes for the high
prevalence of GER (43%) in these patients (69). Transient lower
esophageal sphincter relaxation is the main mechanism under-
lying GER events in them (70). GER may induce apneic spells
or barking cough during infancy, aspiration-related pneumo-
nia, or chronic respiratory disease. However, there is a subset
of patients in which the correlation between GER and respira-
tory symptomatology is not clear. In fact, Soto et al. reported
that only 25% of the 70% cases of respiratory distress during
the first year of life were GER-related (71). Furthermore, Legrand
et al. in a long-term outcome assessment reported a high (75%)
prevalence of abnormalities of pulmonary function and respira-
tory symptoms in survivors of EA±TEF that were not associated
with GER, dysphagia, esophageal dilations, gastrostomy, or fun-
doplication (3). Gischler et al. reported a similar frequency of
respiratory tract infections in refluxing EA±TEF children who
underwent a Nissen fundoplication and those who were treated
conservatively, assuming that reflux is not the major contrib-
utor for this respiratory pathology (2). Banjar did not find a
relationship between GER and the development of chronic lung
disease (72).
TRACHEOMALACIA AND OTHER TRACHEOBRONCHIAL ANOMALIES
Tracheomalacia is the commonest tracheal defect in EA±TEF
involving up to 78% of patients and is clinically relevant in as
many as 10–20% patients (8, 73). The negative intrapleural pres-
sure induced by airway obstruction during respiration seems to be
related to GER (74). The varying degrees of severity depend on the
extension of the deficient tracheal cartilage and increased length
of the transverse muscle in the posterior tracheal wall (30). Tra-
cheomalacia usually is present as barky chronic cough, stridor, and
cyanotic episodes in more severe cases. The prevalence seems to
decrease with age and its relationship with lower respiratory tract
infection or other respiratory symptoms in EA±TEF survivors is
not well established (4).
Congenital tracheal stenosis or web, absence or ectopic right
upper bronchus, congenital bronchial stenosis and hypoplastic
right upper bronchus, as well as a high incidence of atelectasis
have also been described in patients with EA±TEF (22).
Other abnormal tracheal features in EA±TEF are impaired
mucociliary transport due to the replacement of the ciliated
epithelium of the trachea by stratified squamous epithelium (33)
and abnormal intrinsic tracheal innervation (31), both likely play-
ers in the development and chronic nature of some respiratory
symptoms.
Once again, the rodent models of EA±TEF reproduce nearly
identical anomalies. Respiratory tree malformations, disturbed
tracheal innervation, and deformed tracheal rings, which deter-
mine a smaller lumen and a more flaccid trachea, are invariable in
these animals (75–77).
LUNG HYPOPLASIA AND OTHER ABNORMALITIES
Recent research demonstrated that congenital structural defects
of the lung parenchyma itself might also be components of the
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VACTERL association (28). In fact, a number of reports describe
concomitant pulmonary hypoplasia, horseshoe lung, or even lung
agenesis (23–29).
Fetal rats with adriamycin-induced EA±TEF besides showing
tracheobronchial malformations similar to humans also present
lung hypoplasia and abnormal lung innervation (54, 75, 76). In
fact, the abnormal FGF10 and Shh signaling reported in these lungs
suggests a disturbed organogenesis with developmental delay [52,
Fragoso et al. (submitted to publication)]. Because this rat model
closely mimics the EA±TEF/VACTERL human phenotype repro-
ducing the morphological characteristics of the esophagus and
trachea, it suggests that the disturbed lung development described
in this model may also occur in humans with EA±TEF.
SUMMARY AND CONCLUSION
Respiratory morbidity did not improve and is still highly prevalent
in EA±TEF survivors despite the improvement of perinatal and
surgical care, the greater awareness, and more aggressive therapeu-
tic strategies concerning associated morbidity (in particular, GER
disease and surgical treatment of tracheomalacia).
Respiratory morbidity associated with EA±TEF may be due to
numerous players intrinsically related to the malformation itself
or the surgical treatment (with or without complications), and
has been often ascribed to associated disorders like tracheoma-
lacia and GER. Nevertheless, at least in a subset of patients, the
epidemiological profile of the respiratory symptoms and its lack
of relation to associated conditions suggest other causes or predis-
posing factors. Because of the scarcity of pathologic material and
the difficulties for carrying out embryonic studies in humans, the
mutant mice and toxicologic rodent models became invaluable
tools in the research of the pathophysiologic processes involved
in the disturbed morphogenesis. A fetal origin for the individ-
ual predisposition for postnatal lung pathology is supported by
the associated tracheobronchial and lung anomalies, the etio-
logical uncertainty regarding several respiratory symptoms, the
absence of clear risk factors for poor respiratory outcome, and
the unpredictable significance of morbidity in adulthood. Even
small disturbances in the process of morphogenesis may impair
lung growth and/or maturity. This will be translated into post-
natal life as a more or less defective lung growth and/or adaptive
response to injury resulting in greater susceptibility to respira-
tory disturbances. New evidence from experimental models also
seems to support this concept because the majority of rodent mod-
els featuring the EA–TEF phenotype also display abnormal lung
development with different degrees of severity.
In addition to the common embryonic origin of digestive
and respiratory systems, human genes identified in syndromic
cases of EA±TEF have been shown to express themselves dur-
ing lung embryogenesis. These observations allow to hypothesize
that their defective expression may also be translated into lung
morphogenesis and play some role in subsequent respiratory tract
ailments. Both human and experimental research programs are
needed to unveil the abnormal mechanisms of lung organogenesis
in EA±TEF in order to answer some of these clinically relevant
issues.
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